Study of Tivantinib (ARQ 197) Plus Cetuximab in EGFR Inhibitor-Resistant MET High Subjects

NCT01892527 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

43

Enrollment

OTHER

Sponsor class

Conditions

Colorectal Cancer Metastatic
C-met Overexpression

Interventions

DRUG: Tivantinib (ARQ197)

Sponsor

Armando Santoro, MD